Saengrawee Thammawithan

Dr. Saengrawee Thammawithan


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
SSSirinya Sitthirak
Sirinya Sitthirak
SNSodsai Narkpetch
Sodsai Narkpetch
RNRujira Nonsa-ard
Rujira Nonsa-ard
MNManit Nuinoon
Manit Nuinoon
PSPoonsup Sripara
Poonsup Sripara
YRYanisa Rattanapan
Yanisa Rattanapan
Background/Objectives: Early detection of cardiometabolic irregularities is crucial for averting cardiovascular illness; however, demographic cohorts that consistently engage with healthcare systems like habitual blood donors are inadequately leveraged for metabolic monitoring. Methods: This study performed lipid profiling and cardiovascular risk assessment among blood donors identified with visually lipemic plasma during routine screening, in order to explore metabolic variability within this selected donor subgroup. Of 13,818 screened donors, 160 with lipemic plasma were included, and multivariable and machine-learning analyses were restricted to 90 donors with complete clinical data. Results: We observed substantial variability in triglyceride levels, with males displaying higher and more dispersed values. Correlation analysis indicated that triglycerides were associated with BMI and composite cardiovascular risk metrics, while age was the strongest contributor to the calculated 10-year cardiovascular risk score. Using a Random Forest classifier, elevated triglyceride levels were predicted with an AUC of 0.86; however, given the limited sample size, this analysis should be interpreted as exploratory and proof-of-concept in nature. Conclusions: In this selected subgroup of donors with lipemic plasma, clinically relevant hypertriglyceridemia was frequently observed. These findings suggest that routine donor data may provide opportunities for targeted metabolic monitoring, although the results cannot be generalized to the broader blood donor population. Further studies in larger and more representative cohorts are warranted.

9 October 2026 in Oxygen
Verified
Journal Article
Open access
PDF file
SSSirinya Sitthirak
Sirinya Sitthirak
NGNopparut Gota
Nopparut Gota
JCJie Cui
Jie Cui
STSaengrawee Thammawithan
Saengrawee Thammawithan
RNRujira Nonsa-ard
Rujira Nonsa-ard
PKPattamaporn Kwankaew
Pattamaporn Kwankaew
Triple-negative breast cancer (TNBC) is an aggressive and molecularly heterogeneous breast cancer subtype. We developed a six-gene oxidative stress-related signature (BAG5, ANXA2, LONP1, GBE1, CBR1, and DDIT4) in GSE58812 (107 patients; 29 deaths) and evaluated its transportability in GSE21653 (83 TNBC patients; 25 disease-free-survival events). Apparent discovery performance was high (C-index 0.823; 1-, 3-, and 5-year AUCs 0.962, 0.838, and 0.871), but repeated 5-fold out-of-fold evaluation across 50 repeats yielded a lower mean C-index of 0.764, indicating optimism in the apparent estimates. In GSE21653, the fully frozen continuous score showed modest discrimination for disease-free survival (C-index 0.626). The discovery-derived cutoff classified all 83 external patients as low risk; therefore, the categorical classifier was not externally validated and should not be used clinically. Bulk-transcriptome analyses associated higher discovery-cohort risk with hypoxia-related and ferroptosis-protection gene-expression programs and with lower interferon-gamma, cytotoxic T/NK, and antigen-presentation signatures. CD276 and VTCN1 transcript levels were also higher in the high-risk group. These immune and redox findings are transcriptomic associations rather than direct measurements of immune-cell abundance, ferroptosis sensitivity, or checkpoint-protein expression. The signature and its biological associations are therefore hypothesis-generating and require validation in larger endpoint-matched cohorts and functional studies.

23 October 2026 in Oxygen
Verified
Journal Article
Open access
PDF file
YRYanisa Rattanapan
Yanisa Rattanapan
KSKrittamate Saisuwan
Krittamate Saisuwan
STSaengrawee Thammawithan
Saengrawee Thammawithan
RNRujira Nonsa-ard
Rujira Nonsa-ard
SSSirinya Sitthirak
Sirinya Sitthirak
Oxidative stress contributes to acute myeloid leukemia (AML) biology and treatment resistance, but its prognostic relevance remains incompletely defined. We analyzed 553 patients from GSE37642, treating paired GPL96/GPL97 measurements from 417 patients as the discovery cohort and GPL570 (n = 136) as a platform-defined internal–external validation cohort. Human genes annotated to cellular response to oxidative stress (GO:0034599) were retrieved from the Enrich GO Biological Process 2023 library; 110 genes were measurable in both cohort definitions. Discovery-only preprocessing was frozen before validation. Seventeen genes with nominal univariate Cox p < 0.05 entered cross-validated LASSO–Cox modeling, which retained a 13-gene signature (ATP13A2, AKT1, DAPK1, HSPA1A, LRRK2, CPEB2, CAMKK2, CCS, PRKAA1, RBM11, TP53, GPX1, and TPM1). Using the fixed discovery-derived coefficients and median cutoff (0.00807), the score separated high- and low-risk patients in discovery (log-rank p = 3.51 × 10−12; continuous-score HR = 3.24, 95% CI 2.46–4.29; C-index = 0.627, 95% CI 0.591–0.661) and remained associated with survival in platform-defined validation (log-rank p = 0.019; HR = 1.90, 95% CI 1.20–3.00; C-index = 0.580, 95% CI 0.519–0.641). Validation AUCs were 0.590, 0.621, and 0.655 at 1, 3, and 5 years. A fully nested five-fold diagnostic yielded a mean held-out C-index of 0.571. Adding the risk score to age improved the nested-model fit in validation (likelihood-ratio p = 0.028), but the improvement in discrimination was small (Delta C-index = 0.019) and its paired out-of-bag bootstrap 95% CI included zero (−0.070 to 0.056); corresponding Delta AUC intervals also included zero. Schoenfeld diagnostics did not indicate proportional-hazards violations. These findings support a biologically interpretable oxidative-stress-associated prognostic signal with modest cross-platform discrimination, while emphasizing the need for independent contemporary validation before clinical use.